Published in Ther Adv Med Oncol on May 01, 2014
An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. Onco Targets Ther (2015) 0.89
Gastrointestinal hemorrhage due to ileal metastasis from primary lung cancer. World J Gastroenterol (2015) 0.87
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series. Medicine (Baltimore) (2015) 0.85
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget (2016) 0.84
Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain. BMC Cancer (2016) 0.83
Toxicity evaluation of cordycepin and its delivery system for sustained in vitro anti-lung cancer activity. Nanoscale Res Lett (2015) 0.79
Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One (2017) 0.77
Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice. Oncol Lett (2014) 0.77
Cognitive impairments following cranial irradiation can be mitigated by treatment with a tropomyosin receptor kinase B agonist. Exp Neurol (2016) 0.76
Retracted Assessment of intracranial metastases from neuroendocrine tumors/carcinoma. J Neurosci Rural Pract (2016) 0.75
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget (2015) 0.75
Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett (2016) 0.75
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. Onco Targets Ther (2016) 0.75
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res (2016) 0.75
Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep (2017) 0.75
Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget (2017) 0.75
Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Cancer Ther (2017) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer (2002) 3.98
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Distribution of brain metastases. Arch Neurol (1988) 3.11
Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer (2007) 2.88
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.49
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res (2008) 2.30
Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today (2006) 2.21
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer (2005) 1.95
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol (1988) 1.84
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol (2002) 1.79
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol (2004) 1.79
Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain (1994) 1.68
Antitumor effects of bisphosphonates. Cancer (2003) 1.66
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 1.66
Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol (2006) 1.66
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer (2012) 1.62
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology (2004) 1.47
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer (2009) 1.47
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol (2009) 1.39
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer (2004) 1.39
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol (2010) 1.34
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. J Thorac Oncol (2010) 1.33
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer (2009) 1.30
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol (2009) 1.30
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer (2009) 1.29
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol (2011) 1.25
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys (2007) 1.21
Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin (2011) 1.20
Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer (2009) 1.20
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol (2001) 1.19
Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol (2009) 1.17
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol (2001) 1.16
Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer (2006) 1.11
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer (2004) 1.11
Management of bone metastases. Oncologist (2000) 1.05
Translational medicine: cancer pain mechanisms and management. Br J Anaesth (2008) 1.05
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol (2008) 1.02
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology (2003) 1.01
Malignant bone pain: pathophysiology and treatments. Curr Rev Pain (2000) 1.01
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer (2006) 1.00
A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer (2009) 0.99
A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol (2011) 0.99
Epidermal growth factor signalling and bone metastasis. Br J Cancer (2009) 0.98
Corticosteroids as adjuvant analgesics. J Pain Symptom Manage (1994) 0.97
First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest (2002) 0.95
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep (2005) 0.93
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer (2010) 0.93
An update on the treatment of CNS metastases in small cell lung cancer. Cancer J (2008) 0.89
Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J Clin Oncol (2005) 0.88
Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol (2006) 0.88
Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer (2009) 0.87
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer (2008) 0.87
How can we improve the treatment of bone metastases further? Curr Opin Oncol (1998) 0.85
New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol (2006) 0.84
Neuropathic pain in cancer. Br J Anaesth (2013) 0.84
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 0.83
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer (2012) 0.82
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer (2005) 0.82
Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol (2012) 0.79
Managing bone complications of solid tumors. Cancer Biol Ther (2006) 0.79
[Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis]. Clin Calcium (2008) 0.79
The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 0.78
[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers]. Nan Fang Yi Ke Da Xue Xue Bao (2010) 0.78
[The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]. Pneumonol Alergol Pol (1998) 0.78
Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Res (2009) 0.78
Cancer pain--the problem areas. Cancer Surv (1988) 0.77
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors. J Thorac Oncol (2010) 0.76
Bone cancer gain without the pain. Nat Med (2000) 0.76
Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer (2010) 0.76
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer (2013) 1.14
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. Future Oncol (2015) 0.79
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7? J Thorac Dis (2016) 0.78
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. PLoS One (2015) 0.78
Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment. Pharmacol Res (2017) 0.75
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. Onco Targets Ther (2014) 0.75
Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer. Oncotarget (2016) 0.75
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther (2016) 0.75